Claims for Patent: 10,253,331

Summary for Patent: 10,253,331

Title:	Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine
Abstract:	Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-.beta. through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
Inventor(s):	Nemunaitis; John J. (Cedar Hill, TX), Senzer; Neil (Dallas, TX), Maples; Phillip B. (Pilot Point, TX), Rao; Donald (Dallas, TX)
Assignee:	GRADALIS, INC. (Dallas, TX)
Application Number:	15/690,092
Patent Claims:	1. A method of manufacturing a bi-shRNA.sup.furin/GMCSF cancer vaccine, comprising: (a) forming a suspension of tumor cells; (b) transfecting the tumor cells with a bi-shRNA.sup.furin/GMCSF expression vector plasmid comprising (i) a first insert comprising a nucleic acid sequence encoding a human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) cDNA; and (ii) a second insert comprising a nucleic acid sequence encoding a bi-functional short hairpin RNA (bi-shRNA) capable of hybridizing to a furin mRNA transcript; (c) harvesting the transfected tumor cells; and (d) freezing the transfected tumor cells. 2. The method of claim 1, further comprising harvesting a tumor comprising tumor cells from an individual and placing the tumor in an antibiotic solution in a sterile container prior to the formation of the tumor cell suspension. 3. The method of claim 1, wherein the tumor cell suspension is formed by enzymatic dissection, mechanical disaggregation, or any combination thereof. 4. The method of claim 1, wherein the tumor cells are transfected by electroporation with the expression vector. 5. The method of claim 1, further comprising incubating the transfected tumor cells overnight prior to harvesting. 6. The method of claim 1, further comprising rendering the transfected tumor cells proliferation-incompetent prior to freezing. 7. The method of claim 6, wherein the transfected tumor cells are rendered proliferation-incompetent by irradiation. 8. The method of claim 6, wherein the transfected tumor cells are rendered proliferation-incompetent by X-ray irradiation. 9. The method of claim 1, wherein the transfected tumor cells are enumerated and aliquoted prior to freezing. 10. The method of claim 1, wherein the tumor cells are derived from a melanoma, a non-small-cell lung cancer, a gall bladder cancer, a colorectal cancer, a breast cancer, a ovarian cancer, a liver cancer, or a Ewing's sarcoma. 11. The method of claim 1, further comprising incubating the transfected tumor cells with .gamma.IFN after transfection. 12. The method of claim 11, wherein the transfected tumor cells are incubated with about 100 U/ml of .gamma.IFN for 48 hours or about 500 U/ml of .gamma.IFN for 24 hours. 13. The method of claim 1, wherein the first insert is operably linked to a promoter. 14. The method of claim 13, wherein the second insert is operably linked to the promoter. 15. The method of claim 13, wherein the promoter is a CMV mammalian promoter and the expression vector further comprises a CMV IE 5' UTR enhancer sequence and a CMV IE Intron A sequence. 16. The method of claim 1, wherein the expression vector further comprises a picornaviral 2A ribosomal skip peptide sequence between the first and the second nucleic acid inserts. 17. The method of claim 1, wherein the bi-shRNA is capable of hybridizing within the 3' UTR region of the furin mRNA transcript. 18. The method of claim 1, wherein second insert comprises: (a) a first stem loop structure comprising (i) a first guide sequence capable of hybridizing to a furin mRNA transcript; and (ii) a first passenger sequence fully complementary to the first guide strand; and (b) a second stem loop structure comprising (i) a second guide sequence capable of hybridizing to a furin mRNA transcript; and (ii) a second passenger sequence partially complementary to the second guide strand. 19. The method of claim 18, wherein the second passenger sequence has a three basepair mismatch with the second guide sequence at positions 9 to 11 of the second passenger strand. 20. The method of claim 19, wherein the second insert comprises a nucleic acid sequence encoding a bi-functional short hairpin RNA (bi-shRNA) according to SEQ ID NO: 2.

Details for Patent 10,253,331

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-12-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-12-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-12-23